Multiple sclerosis experimental therapies

Pluchino S, Furlan R, Martino G (2004) Cell-based remyelinating therapies in multiple sclerosis Evidence from experimental studies. Curr Opin Neurol 17 247-255. 

Schumacher GA, Beebe GW, Kibler RF, Kurland LT, Kurtzke IF, McDowell F, Nagler B, Sibley WA, Tourtelotte WW, Willmon TL (1965) Problems of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 122 522-568. 

The effect of berbamine on experimental allergic encephalitis (EAG) was investigated in Lewis rats. Amelioration of the acute-phase of EAE was only minimal, but the incidence of relapsing EAE was reduced by 65% for berbamine at a non-toxic treatment dosage of 60 mg/kg via gavage on alternate days. These results suggest that berbamine, and perhaps other bisbenzylisoquinoline alkaloids, may have a potential role in the therapy of progressive multiple sclerosis [189]. 

Gran, B. N. Tabibzadeh A. Martin E.S. Ventura J.H. Ware G.-X. Zhang J.L. Parr A.R. Kennedy A. M. Rostami. The protease inhibitor, Bowman-Birk Inhibitor, suppresses experimental autoimmune encephalomyelitis a potential oral therapy for multiple sclerosis. Mult. Scler. 2006, 12, 688. 

Paty, D.E., Willoughby, E., and Whitakek, J. 1992. Assessing the outcome of experimental therapies in multiple sclerosis. In Treatment of Multiple Sclerosis Trial Design, Results, and Future Perspectives, pp. 47-90. London, Springer-Verlag. 

---